Biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) announced first-quarter 2025 financial results, reporting an increase in revenue and adjusted earnings. The company reported
AbbVie Q1 2025 adjusted earnings increase on 8% revenue growth; beat estimates
